

#### MTN-038 Overview of Data Collection and Management

#### Amanda Brown, Lead CDM SCHARP Seattle, WA

- What we will cover
  - Rave/PTID basics
  - Randomization
  - Form population dynamics
  - MTN038-specific forms
  - Where to find more information



- What we will <u>not</u> cover
  - CASI
  - Rave manual
  - Query management
  - CCGs
  - Atlas
  - SSPs



- What we will cover
  - Rave/PTID basics
  - Randomization
  - Form population dynamics
  - MTN038-specific forms
  - Where to find more information



• "Add Subject" generates a PTID

|     | MTN038    | 器 Test2                    |                    |
|-----|-----------|----------------------------|--------------------|
| Sul | oject     | Advanced Search C Add Subi | ⊽T<br>⊳¢           |
|     | Subject   |                            |                    |
| 8   | 991164936 |                            |                    |
| &   | 991457964 |                            | $\triangleright$ ( |
| 0   | 001400025 |                            |                    |

• PTID structure

| CRS Name    | DAIDS ID | Rave ID |  |
|-------------|----------|---------|--|
| Birmingham  | 31788    | 821     |  |
| Pittsburgh  | 1001     | 702     |  |
| Bridge (SF) | 30305    | 764     |  |
|             |          |         |  |

Unique 9 digit identifier



• The PTID-Name Linkage Log must be completed in real time. It is considered a source document for assigning PTIDs to participants.

|   | Participant ID | Name | Date<br>ddMMMyy | Initials |
|---|----------------|------|-----------------|----------|
| 1 |                |      |                 |          |
| 2 |                |      |                 |          |
| 3 |                |      |                 |          |
| 4 |                |      |                 |          |
| 5 |                |      |                 |          |
| 6 |                |      |                 |          |
| 7 |                |      |                 |          |

• Direct data entry is strongly recommended. Site Data Management SOP should address data that will not be direct-entered.

- What we will cover
  - Rave/PTID basics
  - Randomization
  - Form population dynamics
  - MTN038-specific forms
  - Where to find more information



### Randomization

- Approx. 48 participants will be randomized in a 2:1 ratio to either 1.4 g TFV IVR or to a placebo IVR.
- The timing of biopsies will also be randomly assigned.
  - Both of these randomizations take place within the database.
- In addition, approx. 24 participants will be randomly selected for In-Depth Interviews (IDIs).
- The randomization schemes will be generated and maintained by the MTN SDMC and specified in the MTN-038 SSP manual.

## Randomization

- Participants will be randomized to In-Depth Interviews (IDIs) outside of Medidata Balance.
  - MTN SDMC will provide separate
     IDI randomization lists to each site.
  - After treatment group and biopsy schedule randomization in
     Balance, use the Randomization
     ID to find the IDI group on the IDI randomization list.

| Randomization ID | Consider for IDI |
|------------------|------------------|
| 201              | Yes              |
| 202              | Yes              |
| 203              | No               |
| 204              | No               |
| 205              | No               |
| 206              | Yes              |
| 207              | Yes              |
| 208              | Yes 26           |
| 209              | No TNOS          |
| 210              | Yes              |
| F10              | Yes              |
| n le 212         | Yes              |
| EXallie 213      | No               |
| 214              | No               |
| 215              | No               |
| 216              | No               |
| 217              | Yes              |
| 218              | Yes              |
| 219              | Yes              |
| 220              | Yes              |
| 221              | No               |
| 222              | Yes              |
| 223              | Yes              |
| 224              | Yes              |

#### Randomization

- Document IDI Randomization on Enrollment CRF
  - Randomization ID can be found on the Randomization CRF in the Enrollment visit



- What we will cover
  - Rave/PTID basics
  - Randomization
  - Form population dynamics
  - MTN038-specific forms
  - Where to find more information



 When you assign a PTID, all forms for Screening and Enrollment are automatically generated within a participant's visit folder, including Ongoing Logs

| © 991467964  | MTN038 MTRest2        | <u>8</u> 991457964 | V1 - Screening<br>Screening Date of Visit<br>Demographics<br>Hematology   | Subject: 991457964<br>Page: Screening Date of Vis<br>Screening visit date |
|--------------|-----------------------|--------------------|---|---|
| Ongoing Logs | Visit V2 - Enrollment |                    | Inclusion/Exclusion Crite<br>Pregnancy Test Results<br>Medical History Y/N<br>Physical Exam<br>Vital Signs<br>Chemistry Panel - LFT,<br>RFT, Other<br>Pelvic Exam<br>HIV Test Results<br>STI Test Results | Printable Version View PDF 1<br>CRF Version 1116 - Page Generate          |

• In order to populate the remaining visit folders for each participant:

1) In the V1 - Screening folder, on the Inclusion/Exclusion Criteria form, click "Yes", in response to "Did the participant meet all eligibility criteria?"

|   | MTN038 8 Test2 9 991457964 7 V1 - Screening   | Inclusion/Exclusion Criteria |
|---|---|------------------------------|
| <ul> <li>V1 - Screening</li> <li>Screening Date of Visit</li> <li>Demographics</li> <li>Hematology</li> </ul> | Subject: 991457964<br>Page: Inclusion/Exclusion Criteria - V1 - Screening<br>Did the participant meet all eligibility criteria? | Yes ○ No                     |
| Inclusion/Exclusion Criter Pregnancy Test Results   | Informed Consent Date   |                              |
| P Madical History V/N   | FREEDOM OFFICE  |                              |

• In order to populate the remaining visit folders for each participant:

2) ... and in the Enrollment folder, on the Randomization form, click "yes" on "Is the participant ready to be randomized?" Click "save", and all the remaining visit folders will populate.

|  | MTN038 & Test2 99117358 2 - Enrollment Randomization       |            |     |      |
|--|--|------------|-----|------|
| Content 1 Sector 2 Se |  |            |     |      |
| Randomization  | Subject: 991173581<br>Page: Randomization V2 - Encolloneni |            | 1   | 9    |
| Enrollment   | Is the participant ready to be randomized?                 | 0.0        |     |      |
| Pregnancy Test Results   | is the participant ready to be randomized?                 | ● Yes ○ No | 0 0 |      |
| Physical Exam  | Randomization Date and Time?                               |            | OX  | 8 10 |
| Vital Signs  |  |            | 0 r |      |
|  |  |            |     |      |

 Regardless of whether or not a participant ultimately enrolls, please complete the Inclusion Exclusion Criteria and Demographics forms in the Screening folder for everyone who signs a consent form.

- For every follow-up visit (V3-10), the "Follow-Up YN" form needs to be completed in order to populate the remainder of the forms for that visit.
- It is now standard for YN CRFs to populate their respective CRFs
  - this is a change! used to have summary forms, now you need to fill out the YN form first
- Once a particular YN CRF has been completed with "Yes", the respective CRF will populate for subsequent visits

- The Demographics CRF you complete at Screening uses calculated age and other data to populate the lab module in Medidata.
- In Chemistry and Hematology CRFs, select lab FIRST:

Select your local lab first so that laboratory reference ranges can auto populate for each analyte being entered on the form.

|   |   | ing            |
|---|---|----------------|
| <u>V1 - Screening</u> Screening Date of Visi     Demographics | Subject: 991457964<br>Page: Hematology - V1 - Screening | ₿<br> }        |
| Hematology  | HEMOGRAM  |                |
| Inclusion/Exclusion Cr  | Was a hematology sample collected?                      | OYes ONo ◎ 8 🛛 |
| Medical History Y/N     Dhysical Exam                         | Hematology collection date                              |                |

- Screening Forms
  - No AEs expected at Screening or Enrollment



- To Add Pregnancy & Interim visits
  - Find the "Add Event" dropdown menu
  - Menu located at the bottom of the ppt "home" page

| 3 991559168 3 V1 - Screening   | ^ | 3 | Participant Identifier |      |
|--------------------------------|---|---|------------------------|------|
| V2 - Enrollment V3 - Day 1 (1) |   |   | Visit                  | Date |
| 🗇 V4 - Day 7 (1)               |   | 7 | V2 - Enrollment        |      |
| 🗇 V5 - Day 14 (1)              |   | 1 | V9 - Day 91 (1)        |      |
| 🗂 V6 - Day 28 (1)              |   | 7 | V10 - Day 92 (1)       |      |
| 🗂 V7 - Day 42 (1)              |   | - |                        |      |
| 🗂 V8 - Day 56 (1)              |   |   |                        |      |
| 🔂 V9 - Day 91 (1)              |   |   |                        |      |
| 🔂 V10 - Day 92 (1)             |   |   |                        |      |
| Discontinuation (1)            |   |   |                        |      |
| 🔁 Pharmacy (1)                 |   |   |                        |      |
|                                |   |   |                        |      |

- What we will cover
  - Rave/PTID basics
  - Randomization
  - Form population dynamics
  - MTN038-specific forms
  - Where to find more information



- PK Endpoints (Primary)
  - TFV concentrations in plasma
  - TFV concentrations in CVF
  - TFV concentrations in rectal fluid
  - TFV and TFV-DP concentrations in cervical tissue
  - Particular attention to timed specimen CRFs
    - <u>Timed cervical specimen storage</u> at enrollment (v2.0) and v9.0
    - <u>Timed specimen storage</u> at PUEV/v9 when ring is removed
    - Timed versions will supplant the "normal" forms

- Safety Endpoints (Primary)
  - "The proportion of participants with Grade 2 or higher genitourinary adverse event"
  - "The proportion of participants with Grade 3 or higher adverse event"

- Secondary Endpoints
  - Frequency of study IVR removal/expulsions
  - IVR use initiation and persistence
  - Degree to which study participants liked or disliked using the IVR

- Adverse Event (AE) Data
  - Report only <u>one</u> diagnosis, symptom or sign per page
    - Record unifying diagnosis whenever possible
  - Avoid using abbreviations
  - Review for correct spelling
    - Variations in spelling can lead to differences in AE coding, so similar AEs will appear differently in AE safety reports
  - Do not report surgeries as AEs (these are treatments)

- Adverse Event (AE) Data
  - Report ASAP, no later than 3 days following awareness
  - severity grading per usual
  - relationship to study product per usual
  - Action taken w/ study product per usual
  - SAE or EAE reporting per usual

• Visit Windows



- All enrollment procedures must occur on the same day.
- The participant's menstrual cycle must be considered when scheduling Visit 2-Enrollment (Day 0). Ideally, no bleeding should occur within the first 7 days of product use, e.g., Study Visits 2-4 (Days 0, 1, and 7).
- IVR provided at Visit 2, and collected at Visit 9.
- Participants will be randomized to provide cervical tissue samples at either Visits 5 and 8 (Days 14 and 56) or at Visits 6 and 9 (Days 28 and 91).

#### • Visit Windows

| MTN-038 Visit Windows                                  |   |        |        |                               |                       |  |  |  |
|--|---|--------|--------|-------------------------------|-----------------------|--|--|--|
| All windows are in days.                               |   |        |        |                               |                       |  |  |  |
|  | Visit   | Target | Window |                               | Visit Window          |  |  |  |
| Visit  | Code  | Day    | Opens  | Window Closes                 | Length                |  |  |  |
| Screening  | Screening 1.0 NA $\leq$ 45 days prior to Enrollment |        |        |                               |                       |  |  |  |
| Visit 2 - Enrollment (Day 0)                           | 2.0   | 0      | NA     | 45 days after Screening Visit | 45 days               |  |  |  |
| Visit 3 - Day 1  | 3.0   | 1      | 1      | 1                             | 1 day (Target only)   |  |  |  |
| Visit 4<br>Day 7/Week 1                                | <mark>4.</mark> 0                                   | 7      | 6      | 8                             | 3 days (Target +/- 1) |  |  |  |
| Visit 5<br>Day 14/Week 2                               | 5.0   | 14     | 12     | 16                            | 5 days (Target +/- 2) |  |  |  |
| Visit 6<br>Day 28/Week 4                               | 6.0   | 28     | 25     | 31                            | 7 days (Target +/- 3) |  |  |  |
| Visit 7<br>Day 42/Week 6                               | 7.0   | 42     | 39     | 45                            | 7 days (Target +/- 3) |  |  |  |
| Visit 8<br>Day 56/Week 8                               | 8.0   | 56     | 53     | 59                            | 7 days (Target +/- 3) |  |  |  |
| Visit 9<br>Day 91/Week 13                              | 9.0   | 91     | 89     | 93                            | 5 days (Target +/- 2) |  |  |  |
| Visit 10     92     24 - 72 hours after PUEV (Visit 9) |   |        |        | 3 days (Target + 2)           |                       |  |  |  |

#### • "Local Labs" CRFs changed to CHEM and HEME

|  |  | 월 Test2                  | 8 991457964                       | 🗇 V1 - Screening                         | Screening Date of Visit |
|--|--|--------------------------|-----------------------------------|--|-------------------------|
| V1 - Screening Screening Date of Visi Demographics Hematology  | Subject: 99145796<br>Page: Screening<br>Screening visi | 64<br>Date of<br>it date | Visit - V1 - Scr                  | eening                                   | v                       |
| <ul> <li>Inclusion/Exclusion Cr</li> <li>Pregnancy Test Result</li> <li>Medical History Y/N</li> <li>Physical Exam</li> <li>Vital Signs</li> <li>Chemistry Panel - LFT<br/>RFT, Other</li> </ul> | Printable Version<br>CRF Version 1116 - Pa             | View PD<br>age Genera    | F Icon Key<br>ited: 31 Aug 2018 1 | 12:28:19 Pacific Dayli <mark>gh</mark> t | Time                    |
| <ul> <li>Pelvic Exam</li> <li>HIV Test Results</li> <li>STI Test Results</li> </ul>  |  |                          |                                   |  |                         |

#### Split Visits

- A visit is a split visit when the required visit procedures are split (done) over 2 or more days
- The days must *all* fall within allowable visit window; any required procedures not done within allowable window are missed
- For split visits, only 1 Follow-up Visit Summary eCRF is completed, and the Visit Date on this CRF is the date of the first part of the split visit
  - All CRFs completed for the split visit within the applicable study visit folder (e.g., CRFs completed for a split Visit 6 across Days 27 and 28 would all have visit code 6.0)

#### Interim Visits

- Visits that take place between scheduled visits
  - Additional study procedures and/or data collection conducted outside of what is specified in protocol for required study visit (Example: Report of new AE, issue with study product, etc.)
  - Required study visit procedures conducted outside visit window, either to make up certain procedures from missed visit or conduct Visit 9 Early Termination Visit procedures due to early product discontinuation
- All interim contacts (e.g., phone calls and/or clinic visits) will be properly documented in study files and on applicable CRFs

#### **Missed Visits**

- A visit is missed when:
  - No part of a visit is conducted within the allowable visit window, OR,
  - A visit does not have a window, and the participant cannot come in on target day.
    - For 038, the visit that meets this definition is Visit 3.
- Missed visits are not made up. Rather, sites should make every attempt to retain participants at future visits.

If a participant does miss a visit:

- Document in the database using the Missed Visit CRF
- The Missed Visit form will let SCHARP know not to expect any other forms for that participant at that study visit (with the exception of the Follow-up Yes/No CRF).
- The Missed Visit CRF is completed in lieu of a Protocol Deviations Log CRF



- What we will cover
  - Rave/PTID basics
  - Randomization
  - Form population dynamics
  - MTN038-specific forms
  - Where to find more information



- CRF Completion Guidelines (CCGs) to aid in form completion will be available on the MTN-038 ATLAS webpage
- Help text available on select items within Rave to provide key guidance on form completion
- Site Specific Procedures (SSPs) will also provide data-related guidance.

- Last Day to Enroll calendar tool
  - Will be available on study website
  - https://mtnstopshiv.org/research/studies/mtn-038
  - Example from MTN 036

|  | Network   | Research                                 | People             | Meetings         | Resources                      |  |
|--|---|--|--------------------|------------------|--------------------------------|--|
| Research > Studies > MTN-036/IPM                             | 047   |  |                    |                  |                                |  |
| MTN-036/IPM (  |   |  |                    |                  |                                |  |
| MTN-036/IPM 047 is a Phase 1, safety and pharmacokinetics (P | <b>Study Links</b><br>Clarification Memos   |  |                    |                  |                                |  |
| 25 mg or 200 mg of the active in                             | ngredient dapivirine  | (DPV) formulated u                       | using either polyr | mer 4320 or      | Internal Documents             |  |
| 4870. Approximately 36 healthy                               | HIV-uninfected, nor<br>7 days Participants  | n-pregnant women<br>will insert one VR t | between 18-45 y    | ears of age will | Letters of Amendment           |  |
| days (200 mg VRs) or replaced                                | Operational Guidance  |  |                    |                  |                                |  |
| months. MTN-036/IPM 047 will                                 | months. MTN-036/IPM 047 will collect local and systemic pharmacokinetic data as well as safety information on the vaginal rings. MTN-036/IPM 047 will also investigate the acceptability of and |  |                    |                  |                                |  |
| information on the vaginal rings                             |   |  |                    |                  |                                |  |
| adherence to the VRs and explo                               | re changes in vagina  | al microflora and bi                     | iomarkers over 9   | 0 days of        | Study Implementation Materials |  |
| product use.   |   |  |                    |                  |                                |  |

#### • Example from MTN034

| 👌 MTN-034 Study Implementatio 🗙 🕂  |            |            | $\times$ |
|--|------------|------------|----------|
| → C û I https://mtnstopshiv.or ··· V ☆   | R Search   | <u>↓</u> × | > ≡      |
| Other Tools/Templates  |            |            | ^        |
| HIV Confirmation Procedures Guide (Download)   | 2018-08-10 | 45.37 KB   |          |
| Pregnancy Participant Follow-up Visit Checklist<br>(Download)  | 2018-08-10 | 44.05 KB   |          |
| Pregnant Participant Procedures Guide (Download)   | 2018-08-10 | 41.84 KB   |          |
| Seroconverter Follow-up Visit Checklist (Download)   | 2018-08-10 | 45.41 KB   |          |
| Visit Scheduling Tool (Includes Last Day to Enroll Tool,<br>Follow-up Visit Calendar, Seroconverter Specimen<br>Scheduling Tool) <u>(Download)</u> | 2018-06-11 | 22.36 KB   |          |

| E   | 5.6.8   | * ÷    |                  |                              |                         |                        | m034  | _visit_calendart | ool_v1.0_06112018.xls  | x [Read-Only] - Excel                |  |
|-----|---|--------|------------------|------------------------------|-------------------------|------------------------|---|------------------|--|--------------------------------------|--|
| Fil | e Home  | Insert | Page Layout      | Formulas                     | Data                    | Review                 | View  | ACROBAT          | ♀ Tell me what yo  | ou want to do                        |  |
| F1  | •   | ×      | √ f <sub>x</sub> |                              |                         |                        |   |                  |  |                                      |  |
|     | Α   |        | В                |                              |                         |                        |   | С                |  | D                                    |  |
| 1   | MTN-034 - Calculation of Last P   |        |                  |                              | Pos                     | Possible Day to Enroll |   |                  | Instructions:  |                                      |  |
| 23  |   |        |                  |                              |                         |                        |   |                  |  | 1. Enter Screeni<br>order to generat |  |
| 4   | Screening Visit Date:<br>Date Screening Consent marked or signed                              |        |                  |                              | Monday, January 8, 2018 |                        |   | REACH.           |  |                                      |  |
| 5   |   |        |                  |                              |                         | Enter as dd-mmm-yy     |   |                  |  | method of contra                     |  |
| 6   |   |        |                  |                              |                         |                        |   |                  |  | generate the firs                    |  |
| 7   | Date participant initiates effective<br>method of contraception:                              |        |                  |                              |                         | Wedne                  | enrolled based o<br>criteria #9. Do no<br>participant prior |                  |  |                                      |  |
| 8   |   |        |                  |                              |                         |                        | Enter a   | as dd-mmm        | -уу  |                                      |  |
| 9   |   |        |                  |                              |                         |                        |   |                  | 119/3+2-   |                                      |  |
| 10  | First possible Enrolment date based on<br>initiation of effective method of<br>contraception: |        |                  | on<br>Sunday, March 11, 2018 |                         |                        |   |                  | Per inclusion criter<br>must use an effe<br>contraception for a<br>prior to En |                                      |  |
| 11  |   |        |                  |                              |                         |                        | Shown   | as dd-mmn        | п-уу   |                                      |  |
| 12  |   |        |                  |                              | -                       |                        |   |                  |  |                                      |  |
|     |   | act F  | av to Enrol      |                              |                         | Max                    | adau  | Marah di         | 0 2049   |                                      |  |

- For non-protocol specific overviews:
  - https://mtnstopshiv.org/research/studies/mtn-020/study-implementation-materials/clinicalresearch-training
- For Medidata RAVE:
  - www.imedidata.com
- For help with ATLAS:

– https://atlas.scharp.org/

#### Questions?



Amanda Brown, CDM abrown@scharp.org